EGFR and non-small cell lung carcinoma: JBJ-04-125-02 was also an EGFR allosteric inhibitor that could inhibit proliferation of the NSCLC cells with EGFR triple mutants in vitro and in vivo, and combination of JBJ-04-125-02 and osimertinib resulted in increased apoptosis compared with the treatment with JBJ-04-125-02 or osimertinib alone [121].